Evidence map›Paper›PMID 27344059›Full record

ArticleJournal of thrombosis and haemostasis : JTH2016

Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami.

T Obser, M Ledford-Kraemer, F Oyen, M A Brehm, C V Denis, R Marschalek, R R Montgomery, J E Sadler, S Schneppenheim, U Budde and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

T ObserDepartment of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
M Ledford-KraemerCLOT-ED, Inc., Islamorada, FL, USA.
F OyenDepartment of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
M A BrehmDepartment of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
C V DenisINSERM UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicetre, France.
R MarschalekInstitute of Pharmaceutical Biology/ZAFES/DCAL, Biocenter, Johann-Wolfgang-Goethe-University Frankfurt, Frankfurt/Main, Germany.
R R MontgomeryBlood Research Institute of Blood Center of Wisconsin and Medical College of Wisconsin, Milwaukee, WI, USA.
J E SadlerDepartments of Medicine and Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, USA.
S SchneppenheimMedilys Central Laboratory Coagulation, Asklepios Clinic Altona, Hamburg, Germany.
U BuddeMedilys Central Laboratory Coagulation, Asklepios Clinic Altona, Hamburg, Germany.
R SchneppenheimDepartment of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. schneppenheim@uke.de.
Asklepios Klinik Altona · DEUniversität Hamburg · DEUniversity Medical Center Hamburg-Eppendorf · DEGoethe University Frankfurt · DEMedical College of Wisconsin · USUniversité Paris-Saclay · FRWashington University in St. Louis · US

Funding

Zimmerman Program for the Molecular and Clinical Biology of VWDP01HL081588 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2005 to 2016
$19.3M
Translational Research Skills Development CoreU54HL112303 · NHLBI · WASHINGTON UNIVERSITY · PI SADLER, J EVAN · 2012 to 2016
$8.8M
VON WILLEBRAND FACTOR MULTIMER ASSEMBLY AND STRUCTURER01HL072917 · NHLBI · WASHINGTON UNIVERSITY · PI SADLER, J EVAN · 2003 to 2012
$4.4M
Comparative Effectiveness in the Diagnosis of VWDR01HL112614 · NHLBI · VERSITI WISCONSIN, INC. · PI ABSHIRE, THOMAS CALVIN, MONTGOMERY, ROBERT R · 2013 to 2018
$4.1M
NHLBI NIH HHS P01 HL081588NHLBI NIH HHS R01 HL072917NHLBI NIH HHS R01 HL112614NHLBI NIH HHS U54 HL112303
6 · The paper itself

Abstract

unlabelledEssentials Von Willebrand disease IIC Miami features high von Willebrand factor (VWF) with reduced function. We aimed to identify and characterize the elusive underlying mutation in the original family. An inframe duplication of VWF exons 9-10 was identified and characterized. The mutation causes a defect in VWF multimerization and decreased VWF clearance from the circulation. SUMMARY: Background A variant of von Willebrand disease (VWD) type 2A, phenotype IIC (VWD2AIIC), is characterized by recessive inheritance, low von Willebrand factor antigen (VWF:Ag), lack of VWF high-molecular-weight multimers, absence of VWF proteolytic fragments and mutations in the VWF propeptide. A family with dominantly inherited VWD2AIIC but markedly elevated VWF:Ag of > 2 U L(-1) was described as VWD type IIC Miami (VWD2AIIC-Miami) in 1993; however, the molecular defect remained elusive. Objectives To identify the molecular mechanism underlying the phenotype of the original VWD2AIIC-Miami. Patients and Methods We studied the original family with VWD2AIIC-Miami phenotypically and by genotyping. The identified mutation was recombinantly expressed and characterized by standard techniques, confocal imaging and in a mouse model, respectively. Results By Multiplex ligation-dependent probe amplification we identified an in-frame duplication of VWF exons 9-10 (c.998_1156dup; p.Glu333_385dup) in all patients. Recombinant mutant (rm)VWF only presented as a dimer. Co-expressed with wild-type VWF, the multimer pattern was indistinguishable from patients' plasma VWF. Immunofluorescence studies indicated retention of rmVWF in unusually large intracellular granules in the endoplasmic reticulum. ADAMTS-13 proteolysis of rmVWF under denaturing conditions was normal; however, an aberrant proteolytic fragment was apparent. A decreased ratio of VWF propeptide to VWF:Ag and a 1-desamino-8-d-arginine vasopressin (DDAVP) test in one patient indicated delayed VWF clearance, which was supported by clearance data after infusion of rmVWF into VWF(-/-) mice. Conclusion The unique phenotype of VWD2 type IIC-Miami results from dominant impairment of multimer assembly, an aberrant structure of mutant mature VWF and reduced clearance in vivo.

Indexed as

MutationAdultAgedAnimalsDeamino Arginine VasopressinEndoplasmic ReticulumFemaleGenes, DominantGenes, RecessiveGenotypeHumansMaleMiceMice, Inbred C57BLMiddle AgedPhenotypeDeamino Arginine VasopressinRecombinant Proteinsvon Willebrand FactorADAMTS-13, mousegeneticsphysiopathologyvon Willebrand disease, type 2Avon Willebrand factor

Identifiers

PMID27344059
PMCPMC5035592
OpenAlexW2468791125

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.